Prothena (PRTA)
(Delayed Data from NSDQ)
$6.81 USD
-0.06 (-0.87%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.80 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Prothena Corporation plc has a market cap of $369.79M, which represents its share price of $6.87 multiplied by its outstanding shares number of 53.83M. As a small-cap company, PRTA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PRTA 6.81 -0.06(-0.87%)
Will PRTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRTA
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Other News for PRTA
Prothena (PRTA) Set to Report Q2 Earnings Amid Workforce Cuts
Prothena Q2 2025 Earnings Preview
A Glimpse of Prothena Corp's Earnings Potential
Prothena to Report Second Quarter 2025 Financial Results on August 4 | PRTA Stock News
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)